Outpace Bio, Inc.

12:00 PM - 12:15 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 103
Outpace is pioneering the era of curative cell therapies using protein design and cellular engineering. With an initial focus on solid tumors, Outpace is creating technologies that overcome the barriers to efficacy and safety by programming cells to make the right decisions inside patients. Outpace’s suite of technologies drive persistent activity of the cell therapy (OutLast™), recruit a productive immune response in the tumor microenvironment (OutSmart™), and achieve the potency (OutSpacer™), specificity (Co-LOCKR™), and safety (EGFRopt™) necessary to unlock diverse cancer indications. Outpace’s internal and partnered pipeline approach is optimized for rapid clinical validation of its technologies across diverse cell types and manufacturing processes. Outpace is based in Seattle, Washington. To learn more, visit outpacebio.com and follow on Twitter and Instagram @OutpaceBio.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
Autologous CAR-T for Solid Tumors with Outpace Technologies
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Founder and Chief Executive Officer
Outpace Bio, Inc.